Cannabis markets itself unusually heavily on values — wellness, sustainability, social justice, community. More than most consumer sectors, it invites being held to the standard it advertises.
Measured against that standard, the record is uneven. These are the questions the industry has not resolved.
The Legacy of Enforcement
The industry exists because a prohibition ended. That prohibition was enforced unevenly, and people are still carrying its consequences while a legal industry profits from the same activity.
The concrete questions are whether prior convictions are being expunged, whether people with those convictions can participate in the legal industry, and whether tax revenue reaches the communities where enforcement concentrated.
Progress has been real and partial. Automatic expungement in states that adopted it has cleared far more records than petition-based processes. Most social equity licensing programmes have underdelivered, largely because a licence does not solve a capital problem. Detail in diversity, equity and inclusion in the cannabis industry.
Labour
Cannabis employs a substantial number of people in cultivation, trimming, processing and retail, and working conditions vary widely.
Trimming in particular has a history of piece-rate work, seasonal insecurity and — in the transition from illicit to legal production — practices that would not survive scrutiny in other agriculture. The legal sector has improved on this by virtue of being visible, and unionisation has advanced in several markets.
Occupational safety is a genuine issue. Extraction work involves flammable solvents under pressure. Cultivation and drying spaces carry mould exposure risk — which is a worker health question as much as a product quality one, as noted in storage and ventilation. Some workers have developed occupational sensitisation to cannabis dust and pollen.
Environmental Footprint
Indoor cannabis production is among the most energy-intensive forms of agriculture, and the industry has been slow to confront this because indoor product commands a price premium.
Water use in drought-prone regions, packaging waste driven by child-resistance requirements, peat-based growing media, and disposal rules that require mixing waste with other material all add to it. Each is covered in sustainability in cannabis cultivation and cannabis waste disposal.
The uncomfortable part is that the lowest-footprint production method — outdoor — is the one the market values least. That is a consumer preference problem as much as an industry one, and it will not resolve through operator goodwill alone.
Marketing and Health Claims
This is where the gap between rhetoric and evidence is widest.
Cannabis is routinely marketed with therapeutic claims that the research does not support. Products are promoted for anxiety, sleep, pain and inflammation on evidence that is preliminary at best, and the confident version reaching consumers runs well ahead of what has been demonstrated. See the science behind medical cannabis research.
The potency arms race is a second problem. Marketing built around THC percentage encourages consumers toward higher-potency products without evidence that higher potency serves them better, and it creates the commercial pressure behind the integrity problems described in lab ethics and data integrity.
And risks are systematically under-communicated. Cannabis use disorder, the association between high-potency use and psychosis risk, cannabinoid hyperemesis syndrome, and interactions with other medications are all documented, and rarely appear in marketing.
Vulnerable Populations
Some groups warrant more care than the industry generally exercises.
Adolescents, where evidence on developing brains is a live concern and where product design and marketing that appeals to young people is a legitimate objection. Pregnant and breastfeeding people, where evidence is limited and caution is warranted. People with psychiatric history, where the psychosis association is strongest. Older adults on multiple medications, where interactions matter more — see cannabis and drug interactions.
Testing and Independence
Within testing specifically, the ethical questions are narrow and consequential.
Producers select and pay the laboratories that assess them, which creates pressure toward accommodating results. Laboratories hold commercially sensitive client data. And the incentive to compete on outcome rather than capability is always present.
The countermeasures are known: accreditation, independent sampling, blind proficiency testing, data integrity controls, and enforcement that is published rather than private. All of it is covered in lab ethics and data integrity.
The reason a laboratory should be willing to state this plainly is that a testing function whose independence is assumed rather than demonstrated is not performing the role it claims.
What Would Constitute Progress
Concrete rather than aspirational:
- Automatic expungement rather than petition-based processes
- Capital access for equity licensees, not licence priority alone
- Marketing claims constrained to what evidence supports
- Risks communicated alongside benefits, as a norm rather than a legal minimum
- Environmental reporting that allows comparison between operators
- Occupational safety treated as seriously as product safety
- Testing independence protected structurally, not left to goodwill
Cannabis has an opportunity most industries do not — it is young enough to establish norms rather than inherit them. Whether it uses that opportunity is still open. The commercial pressures shaping the answer are in the future of the cannabis industry.